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T
he marked increase in new cases of type 2
diabetes observed throughout the world and the
associated comorbidities represent one of the
major health issues we will face in the 21st
century. It is also understood that environmental factors
such as lifestyle habits (i.e., physical inactivity and dietary
intake) and obesity act as initiating factors for progression
to type 2 diabetes. A number of studies have conﬁrmed
that intensive lifestyle modiﬁcation is effective in the
prevention of diabetes in individuals with impaired glu-
cose tolerance (1,2). Although it is well established that
caloric restriction and exercise greatly promote weight
loss and improve insulin resistance for those at risk for
developing type 2 diabetes, the success of lifestyle inter-
vention over a long-term period is poor. Therefore, strat-
egies to improve risk factors related to progression to type
2 diabetes, i.e., insulin resistance, by pharmacologic or
nutritional supplementation represent a very attractive
approach. In this regard, pharmacologic agents have
shown efﬁcacy in diabetes prevention, but adverse events
need to be considered before routine use is recommended
(3,4). In addition, other novel risk factors, e.g., homocys-
teinemia, have been associated with the development of
type 2 diabetes, and cellular mechanisms have been pos-
tulated that provide an understanding for this effect (5).
Until recently, however, there have been no prospective
studies to evaluate whether nutritional interventions
aimed at effectively treating homocysteinemia will reduce
the chances for diabetes development. Nevertheless, the
recently reported observations from the Women’s Antiox-
idant and Folic Acid Cardiovascular Study (WAFACS),
presented in this issue of Diabetes, provide new informa-
tion regarding treating this risk factor and diabetes pro-
gression (6). Speciﬁcally, the results from the study of
Song et al. (6) suggest that a simple attempt to supplement
the diet with folic acid and B vitamins in individuals at
high risk for development of type 2 diabetes does not
attenuate progression to type 2 diabetes (6).
WAFACS was a randomized double-blind placebo-con-
trolled trial that evaluated the effects of a combination pill
of folic acid and vitamins B6 and B12 in the secondary
prevention of vascular events among high-risk women
with prior cardiovascular disease or at least three cardio-
vascular disease risk factors. The study began in 1998
when the vitamin B supplementation component was
added to the Women’s Antioxidant Cardiovascular Study
(WACS), which was an ongoing study evaluating three
antioxidant vitamins, i.e., vitamins C, E, and -carotene.
Speciﬁcally, after excluding women who had diabetes,
4,252 women were evaluated at baseline. The hypothesis
for WAFACS was that elevated homocysteine levels may
contribute to development of insulin resistance and type 2
diabetes and, by effectively treating the levels, the risk for
type 2 diabetes would be lowered. Speciﬁcally, it was
hypothesized that B vitamins may modulate the progres-
sion to type 2 diabetes by improving the contributing
metabolic parameters implicated in the development and
progression to type 2 diabetes such as oxidative damage,
inﬂammation, and endothelial dysfunction (6). Thus, fol-
lowing baseline evaluations, subjects were randomized to
the combination pill (2.5 mg folic acid, 50 mg vitamin B6,
and 1 mg vitamin B12) or a matching placebo. Study
medications and end point ascertainment were continued
in a blinded fashion for a follow-up duration of 7.3 years.
At the end of the study, homocysteine levels were reported
to be signiﬁcantly reduced in the active treatment group by
18.5% (group difference 2.27 mol/l) as compared with that
for the placebo group (geometric group mean level 12.28
mol/l). During the mean follow-up period, 504 women
were diagnosed as having type 2 diabetes: 245 incident
cases (11.5%) in the active treatment group and 259
(12.2%) in the placebo group. The key ﬁnding from the
study was that supplementation of folic acid/B vitamins in
a high-risk patient population did not attenuate progres-
sion to type 2 diabetes.
The strengths of WAFACS included that it was a ran-
domized placebo-controlled trial in a large number of
subjects, i.e., over 2,000 subjects in each arm of study. The
observation period of over 7 years was signiﬁcant. The
determination of onset of the diabetic state appeared to be
well validated and assessed. The limitations of the study
outlined by the authors did include the declining compli-
ance over the course of study, but evaluation restricted to
women who were compliant did not change the results. In
addition, the intervention with a combination pill did not
allow assessment or evaluation of individual components.
Finally, homocysteine levels were not measured in all sub-
jects. Yet, with the stated limitations, WAFACS was carefully
conducted and appropriately evaluated and, as such, did
provide novel and important clinical observations.
The observation from WAFACS does not support rec-
ommendations for folic acid/B vitamins for diabetes pre-
vention. These data are very clinically relevant given the
observations suggesting that elevated levels of homocys-
teine were independently associated with increased diabe-
tes risk and also suggesting that lowering homocysteine
may prevent or reduce risk (5). Clearly, the question
addressed by the investigators was relevant and the trial
From the Joint Diabetes, Endocrinology, and Metabolism Program, Louisiana
State University Health Sciences Center School of Medicine, New Orleans,
Louisiana, and Pennington Biomedical Research Center, Baton Rouge,
Lousiana.
Corresponding author: William T. Cefalu, cefaluwt@pbrc.edu.
DOI: 10.2337/db09-0840
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying original article, p. 1921.
COMMENTARY
1730 DIABETES, VOL. 58, AUGUST 2009needed to be conducted to answer the question. However,
given these ﬁndings, can we really be surprised by the
outcome? Did we really expect such a simple solution to
diabetes progression would be in the form of dietary
supplementation with inexpensive and readily available
nutrients? If anything, this study highlights the current
reality that we are facing in that there are no simple or
easy solutions to diabetes prevention!
What we do deﬁnitively know is that the most effective
strategy for diabetes prevention involves lifestyle modiﬁ-
cations to favorably impact energy balance, i.e., reduce
caloric (energy) intake and increase energy expenditure
with enhanced physical activity (1,2). Thus, the real chal-
lenge we must address is how to successfully implement
and maintain the strategy, i.e., lifestyle modiﬁcation, in the
vast majority of those at high risk for diabetes. What
means can be put in place to ensure that the results from
landmark studies such as the Diabetes Prevention Pro-
gram are commonly seen in clinical practice? Clearly, as a
society and as a medical community, we need to adopt a
different mind-set if we hope to stem the tide of the
diabetes epidemic. With regard to being a priority in
clinical practice, we need to stress a strategy that provides
appropriate resources and fair compensation to providers,
nutritionists, educators, etc., so that they can spend the
required time necessary to counsel patients to achieve
goals directed at diabetes prevention. Such a strategy will
not be inexpensive nor easy! However, given that health
care costs attributed to overweight/obesity are projected
to double every decade and to represent one in every six
USD spent on health care in 2030 (7) as well as with the
complications and mortality attributed to type 2 diabetes,
the real question we must ask is whether we can really
afford not to address this situation.
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